Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4595 in Advanced Solid Tumors
NCT07830199Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-4595 in solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Adverse events, Dose-limiting toxicity at 12 months and 2 more. Started Oct 2026; status: recruiting.
02
Drugs
SHR-4595
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07830199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830199.